Pharmicell파미셀
005690 · KOSPI · ₩005690 · 파미셀
₩10,230▲ ₩430 (4.39%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩114B | ₩65B | ₩56B | ₩60B | ₩51B |
| Cost of sales | ₩63B | ₩44B | ₩41B | ₩36B | ₩27B |
| Gross profit | ₩51B | ₩21B | ₩15B | ₩24B | ₩23B |
| Operating income | ₩34B | ₩4.7B | ₩1.3B | ₩8.9B | ₩7.6B |
| Net income | ₩40B | ₩6.3B | ₩3.6B | ₩11B | ₩9.5B |
| Net income to shareholders | ₩40B | ₩6.3B | ₩3.6B | ₩11B | ₩9.5B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩157B | ₩99B | ₩93B | ₩113B | ₩96B |
| Current assets | ₩95B | ₩48B | ₩43B | ₩62B | ₩67B |
| Cash and equivalents | ₩29B | ₩8.3B | ₩14B | ₩14B | ₩26B |
| Total liabilities | ₩33B | ₩13B | ₩12B | ₩33B | ₩30B |
| Current liabilities | ₩20B | ₩7.6B | ₩7.8B | ₩29B | ₩25B |
| Borrowings | ₩14B | ₩317M | ₩2.4B | ₩17B | ₩17B |
| Total equity | ₩124B | ₩86B | ₩80B | ₩80B | ₩65B |
| Shareholders' equity | ₩124B | ₩86B | ₩80B | ₩80B | ₩65B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩41B | ₩3.5B | ₩13B | ₩7.9B | −₩5.2B |
| Capital spending | ₩7.5B | ₩4.3B | ₩6.5B | ₩19B | ₩4.3B |
| Free cash flow | ₩34B | −₩780M | ₩6.4B | −₩11B | −₩9.5B |
Consolidated where available. Amounts in won.
Also known as: Pharmicell / 파미셀 / 005690 / KRX:005690
Source: KRX statistical information